Form 4 holding
Former Chief Executive Officer
Talaris Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 578,403
- Estimated value
- $9,827,067
- Report date
- 03 Jul 2023
- Price
- $16.99
- Ownership
- Direct
Scott Requadt
Insider Reports History
- Location
- Cambridge, MA
- Owner filing signature
- /s/ Scott Requadt
- Transaction evidence
- Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Who this page is about.
1 identity field
SEC source record
Original filing metadata and source links.
1 source field
Source evidence
Original filing metadata and source links.
1 source field
Reported holdings for Scott Requadt
Form 4 holding
Former Chief Executive Officer
Talaris Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 449,766
- Estimated value
- $7,641,524
- Report date
- 03 Jul 2023
- Price
- $16.99
- Ownership
- Indirect
Form 4 holding
Director
ESSA Pharma Inc.
- Security class
- Common Shares
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 09 Oct 2025
- Price
- $0.2400
- Ownership
- Direct
Insider Reports Filed by Scott Requadt
4
EPIX
ESSA Pharma Inc.
- Report period
- 09 Oct 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Oct 2025, 11:58
- Role
- Director
- Next action
- Open filing details
4
EPIX
ESSA Pharma Inc.
- Report period
- 25 Mar 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 28 Mar 2024, 12:38
- Role
- Director
- Next action
- Open filing details
4
EPIX
ESSA Pharma Inc.
- Report period
- 30 Oct 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 16 Jan 2024, 13:41
- Role
- Director
- Next action
- Open filing details
4
TRML
Talaris Therapeutics, Inc.
- Report period
- 03 Jul 2023
- Transactions
- 1
- Transaction value
- -$36,301
- Accepted by SEC
- 06 Jul 2023, 17:19
- Role
- Former Chief Executive Officer
- Next action
- Open filing details
4
TRML
Talaris Therapeutics, Inc.
- Report period
- 01 Feb 2023
- Transactions
- 3
- Transaction value
- +$3.47
- Accepted by SEC
- 03 Feb 2023, 16:01
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
TRML
Talaris Therapeutics, Inc.
- Report period
- 10 Sep 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Sep 2022, 16:30
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
TRML
Talaris Therapeutics, Inc.
- Report period
- 29 Jul 2022
- Transactions
- 1
- Transaction value
- +$167,374
- Accepted by SEC
- 02 Aug 2022, 17:02
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
TRML
Talaris Therapeutics, Inc.
- Report period
- 26 Jul 2022
- Transactions
- 2
- Transaction value
- +$36,571
- Accepted by SEC
- 28 Jul 2022, 19:52
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
TRML
Talaris Therapeutics, Inc.
- Report period
- 22 Jul 2022
- Transactions
- 1
- Transaction value
- +$35,412
- Accepted by SEC
- 26 Jul 2022, 19:38
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details
4
EPIX
ESSA Pharma Inc.
- Report period
- 29 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 01 Nov 2022, 11:07
- Role
- Director
- Next action
- Open filing details
4
TRML
Talaris Therapeutics, Inc.
- Report period
- 01 Feb 2022
- Transactions
- 2
- Transaction value
- +$19,110
- Accepted by SEC
- 02 Feb 2022, 17:01
- Role
- Chief Executive Officer, Director
- Next action
- Open filing details